Newborn affected by maternal use of cannabis
ICD-10 P04.81 is a billable code used to indicate a diagnosis of newborn affected by maternal use of cannabis.
Newborns affected by maternal cannabis use may present with a variety of symptoms and complications due to the exposure to tetrahydrocannabinol (THC) and other cannabinoids during gestation. Maternal cannabis use can lead to low birth weight, preterm birth, and potential neurodevelopmental issues. The effects of cannabis on the fetus are still being studied, but evidence suggests that it may impact the developing brain and lead to behavioral issues later in life. Newborns may exhibit withdrawal symptoms, such as irritability, tremors, and feeding difficulties. It is crucial for healthcare providers to assess the newborn's condition thoroughly and provide appropriate interventions. Documentation should include maternal history of substance use, any observed symptoms in the newborn, and the care provided in the neonatal intensive care unit (NICU) or nursery. Accurate coding is essential for proper treatment planning and follow-up care.
Detailed maternal history, newborn assessment notes, and any interventions provided.
Newborns presenting with irritability, feeding difficulties, or low birth weight in the NICU.
Consider the potential for withdrawal symptoms and the need for supportive care.
Comprehensive developmental assessments and follow-up care plans.
Pediatric visits for developmental delays or behavioral issues linked to prenatal cannabis exposure.
Monitor for long-term effects on behavior and cognitive development.
Used when assessing a newborn affected by maternal cannabis use.
Document maternal history and newborn assessment findings.
Neonatologists should ensure thorough evaluations are conducted.
Research indicates potential long-term effects on cognitive development and behavior, necessitating ongoing monitoring and support for affected children.
